Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGenedrive Regulatory News (GDR)

Share Price Information for Genedrive (GDR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.675
Bid: 1.60
Ask: 1.75
Change: 0.00 (0.00%)
Spread: 0.15 (9.375%)
Open: 1.675
High: 1.75
Low: 1.675
Prev. Close: 1.675
GDR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

20 Dec 2021 13:08

RNS Number : 2300W
Genedrive PLC
20 December 2021
 

PDMR Dealing

genedrive plc (LSE: GDR) ("genedrive" or the "Company"), the near patient molecular diagnostics company, announces that it has been notified of the following transaction by Matthew Fowler, a person discharging managerial responsibilities, and his wife who is a person closely associated with him.

Following the transfer outlined below, Matthew Fowler's total beneficial interest remains unchanged at 139,457 Ordinary Shares.

This notification is made in accordance with the Market Abuse Regulation. 

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

 

1.

Details of the person discharging managerial responsibilities / person closely associated

a.

Name

Matthew Fowler

 

 

2.

Reason for the notification

a.

Position/status

PDMR, CFO

a.

Initial notification

/Amendment

Initial notification

3.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

genedrive plc

b.

LEI

213800ZYODIRZ87Y4K14

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the

Financial instrument, type

of instrument

Identification code

Ordinary shares of 1.5 pence each

 

 

 

GB00B1VKB244

b.

Nature of the transaction

Transfer of shares to Alison Fowler (spouse) for nil consideration.

c.

Price(s) and volume(s)

 

 

Price £nil

 

Volume(s) 50,000 

 

 

 

 

d.

Aggregated information

·Aggregated volume

·Price

 

 

50,000

 

Nil

 

e.

Date of the transaction

2021-12-20

f.

Place of the transaction

Outside a trading venue

 

For further details please contact:

genedrive plc

+44 (0)161 989 0245

David Budd: CEO / Matthew Fowler: CFO

Peel Hunt LLP (Nominated Adviser and Joint Broker)

+44 (0)20 7418 8900

James Steel 

finnCap (Joint Broker)

+44 (0)20 7220 500

Geoff Nash / Kate Bannatyne / Alice Lane

Walbrook PR Ltd (Media Relations & Investor Relations)

+44 (0)20 7933 8780 or genedrive@walbrookpr.com

Paul McManus / Anna Dunphy

+44 (0)7980 541 893 / +44 (0)7876 741 001

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHEADAEAEKFFFA
Date   Source Headline
30th Nov 20162:16 pmRNSResult of AGM
29th Nov 20167:00 amRNSUpdate on CFO Appointment
17th Nov 20167:00 amRNSCE-IVD Certification for Human Genotyping Test
11th Nov 20165:47 pmRNSNotice of AGM
11th Oct 20167:00 amRNSPreliminary Results for the year end 30 June 2016
21st Sep 20167:00 amRNSNotice of Preliminary Results
21st Sep 20167:00 amRNSAppointment of Chief Financial Officer
10th Aug 20167:00 amRNSGenedrive Assay used in STOP-HCV-1 Clinical Trial
2nd Aug 20167:00 amRNSTrading Update
29th Jul 20165:58 pmRNSTotal Voting Rights
25th Jul 20167:00 amRNSRe change of name, TIDM and website address
14th Jul 20163:56 pmRNSHolding(s) in Company
14th Jul 20168:19 amRNSDirector/PDMR Shareholding
14th Jul 20168:18 amRNSHolding(s) in Company
13th Jul 20162:49 pmRNSHolding(s) in Company
12th Jul 20169:05 amRNSDirector/PDMR Shareholding
11th Jul 201611:34 amRNSResult of General Meeting and Change of Name
23rd Jun 20164:54 pmRNSPosting of Shareholder Circular
23rd Jun 20167:00 amRNSProposed Placing and Amendment to GHIF Bond
7th Jun 20167:00 amRNSBusiness Update
3rd May 20167:00 amRNSSuccessful Clinical Trial of Genedrive®
18th Apr 20167:00 amRNSEpistem Begins Full Commercial Launch of Genedrive
7th Apr 20164:54 pmRNSDirector/PDMR Shareholding
31st Mar 20167:00 amRNSInterim Results
21st Mar 20167:42 amRNSFunding award from US Department of Defense
19th Feb 20167:00 amRNSUpdate on CEO Appointment
18th Feb 20167:00 amRNSAnnounces Successful Assessment of Genedrive
13th Jan 20167:00 amRNSEpistem Appoints David Budd as CEO
16th Dec 20152:18 pmRNSDirector/PDMR Shareholding
16th Dec 20152:11 pmRNSResult of AGM
26th Nov 20154:41 pmRNSHolding(s) in Company
24th Nov 20153:28 pmRNSNotice of AGM
24th Nov 20152:07 pmRNSHolding(s) in Company
28th Oct 20157:00 amRNSPreliminary Results for year ended 30 June 2015
26th Oct 20157:00 amRNSEpistem Holdings Plc - Board Change
20th Oct 20157:00 amRNSNotice of Preliminary Results
15th Oct 20157:30 amRNSDirector/PDMR Shareholding
4th Aug 20157:00 amRNSPre-Close Trading Update and Board Changes
15th Jun 201512:17 pmRNSHolding(s) in Company
8th Jun 20154:49 pmRNSIssuance of Shares
18th May 201512:45 pmRNSNIH Response to UMB proposal
11th May 20153:37 pmRNSAdditional Listing
11th May 201511:53 amRNSDirectorate Change
23rd Apr 20157:00 amRNSRegulatory Approval
13th Apr 20157:00 amRNSUpdate re Indian regulatory approval
2nd Apr 20154:55 pmRNSDirector/PDMR Shareholding
30th Mar 20159:30 amRNSExtension of Director's Options Exercise Period
26th Mar 20157:00 amRNSHalf Yearly Report
11th Feb 20153:21 pmRNSHolding(s) in Company
6th Feb 20157:48 amRNSNotice of Interim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.